Anti-rabies monoclonal antibody - Molecular Targeting Technologies/North China Pharmaceutical Corporation

Drug Profile

Anti-rabies monoclonal antibody - Molecular Targeting Technologies/North China Pharmaceutical Corporation

Alternative Names: Human anti-rabies mAb; NM-57; SO-57; SOJB

Latest Information Update: 19 Oct 2015

Price : $50

At a glance

  • Originator Thomas Jefferson University
  • Developer Molecular Targeting Technologies; North China Pharmaceutical Corporation
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Rabies

Most Recent Events

  • 16 Oct 2015 Phase-II clinical trials in Rabies in China (IM) before October 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top